# NanoMn®_COVID-19 A Prospective, Multicenter, Randomized, Placebo-controlled, Parallel-group, Double-blind Trial to Evaluate the Clinical Efficacy of NanoManganese® on Top of Standard of Care, in Adult Patients With Moderate to Severe Coronavirus Disease 2019 (COVID-19)

> **NCT05451654** · PHASE1,PHASE2 · TERMINATED · sponsor: **Medesis Pharma SA** · enrollment: 7 (actual)

## Conditions studied

- COVID-19 Pandemic

## Interventions

- **DRUG:** Placebo
- **DRUG:** Experimental drug

## Key facts

- **NCT ID:** NCT05451654
- **Lead sponsor:** Medesis Pharma SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-02-04
- **Primary completion:** 2022-10-04
- **Final completion:** 2022-12-01
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** the number of patients recruited was not reached because covid cases were low
- **Last updated:** 2023-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05451654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05451654, "NanoMn®_COVID-19 A Prospective, Multicenter, Randomized, Placebo-controlled, Parallel-group, Double-blind Trial to Evaluate the Clinical Efficacy of NanoManganese® on Top of Standard of Care, in Adult Patients With Moderate to Severe Coronavirus Disease 2019 (COVID-19)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05451654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*